Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Pharma SPA

Division of Merck KGaA

Latest From Merck Pharma SPA

ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod

A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.

Europe Approvals

Archimedes licenses Oramorph for Germany

The UK firm Archimedes Pharmahas licensed from Molteni Farmaceutici the German rights for Oramorph. Oramorph is the only oral liquid immediate-release morphine sulphate product in patient-friendly unit dose vials available in Germany, and acts quickly to initiate morphine therapy in patients with cancer pain. The product is expected to pave the way for the expected launch of Archimedes’s fentanyl nasal spray, Nasalfent, which is currently in Phase III clinical trials. The German immediate-release morphine market is worth around €17.5 million and is growing at 7% per annum.

Cancer Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Molteni Pharma SPA
  • Molteni Farmaceutici
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • Merck KGaA
  • Senior Management
  • Contact Info
  • Merck Pharma SPA
    Phone: (39) 55 73611
    Strada Statale 67
    Scandicci, 50018